Peter Ordentlich - Feb 1, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Scientific Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Feb 1, 2022
Transactions value $
$1,257,185
Form type
4
Date filed
2/3/2022, 04:32 PM
Next filing
Aug 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Other $17.5K +1.41K $12.39 1.41K Jan 31, 2022 Direct F1
transaction SNDX Common Stock Sale -$23.5K -1.41K -100% $16.65 0 Feb 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $1.26M +80K $15.79 80K Feb 2, 2022 Common Stock 80K $15.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,412 shares by the Reporting Person on 01/31/2022 pursuant to the Issuer's Employee Stock Purchase Plan.
F2 1/48th of the shares subject to the option shall vest monthly over a four-year period.